OCCUSYSTEMS, INC. – Trademark Portfolio
Entity Type: 03
OCCUSYSTEMS, INC. holds 16 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 8 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 6 trademarks are registered and 2 are pending. Notable registered marks include M, REX, ADAPT, METHOD, and METHOD INSURANCE. The owner is based in Dallas, TX.
3010 LBJ Freeway, Suite 400
Dallas, TX 75234
Showing of trademarks Trademarks
Trademark Classifications
OCCUSYSTEMS, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Scientific and technological services; industrial analysis and research services
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does OCCUSYSTEMS, INC. have?
OCCUSYSTEMS, INC. has 16 U.S. trademarks filed with the USPTO. Of these, 6 registered, 2 pending, 3 abandoned, 5 cancelled.
What trademark classes does OCCUSYSTEMS, INC. file in?
OCCUSYSTEMS, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 36 (Insurance & Financial), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.
What are OCCUSYSTEMS, INC.'s most well-known trademarks?
OCCUSYSTEMS, INC.'s registered trademark portfolio includes well-known marks such as M, REX, ADAPT, METHOD, and METHOD INSURANCE. These are among 6 currently registered trademarks in the portfolio.
What is OCCUSYSTEMS, INC.'s trademark registration success rate?
OCCUSYSTEMS, INC. has a 43% trademark registration rate, with 6 out of 14 resolved applications resulting in successful registration. Currently, 2 applications are pending review.